Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
We aimed to identify the discriminatory clinical features at diabetes diagnosis of patients with glucokinase (GCK), hepatocyte nuclear factor-1A (HNF1A), and HNF4A MODY in the pediatric population.
|
31704690 |
2020 |
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
The glucokinase exons were sequenced in patients with diabetes.
|
30245511 |
2019 |
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
These clinical indicators could be used as markers of MODY2 and MODY3 in young patients with diabetes.
|
31214998 |
2019 |
Diabetes Mellitus
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Posteriorly, we present a compendium of findings supporting the potential use of nutraceuticals and phytochemicals in the management of diabetes through modulation of GCK expression and activity.
|
31210550 |
2019 |
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
In conclusion, this novel GCK mutant rabbit generated with the CRISPR/Cas9 system mimics most, if not all, histopathological and functional defects seen in MODY-2 patients such as hyperglycemia and will be a valuable rabbit model for preclinical studies and drug screening for diabetes as well as for studying the pathophysiological role of glucokinase.
|
31720743 |
2019 |
Diabetes Mellitus
|
0.200 |
GeneticVariation
|
group |
BEFREE |
This case raises the question as to whether hyperglycaemia in GCK-MODY may increase the risk of fetal caudal regression syndrome as reported in women with pre-existing diabetes mellitus.
|
30362177 |
2019 |
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator.
|
30651321 |
2019 |
Diabetes Mellitus
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Mutations in glucokinase and other genes detected in neonatal and type 1B diabetes patient using whole exome sequencing may lead to disease-causing changes in protein activity.
|
30465894 |
2019 |
Diabetes Mellitus
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Glucokinase (GK) plays a vital role in the control of blood glucose levels and its altered activity can lead to the development of forms of diabetes.
|
30087826 |
2018 |
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
Clinical information and blood for GCK gene analysis were obtained from grandparents with diabetes.
|
29510678 |
2018 |
Diabetes Mellitus
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Molecular reductions in glucokinase activity increase counter-regulatory responses to hypoglycemia in mice and humans with diabetes.
|
30146176 |
2018 |
Diabetes Mellitus
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In contrast, inactivating mutations of GCK result in diabetes, including a mild form (MODY2) and a severe form (permanent neonatal diabetes mellitus (PNDM)).
|
29044608 |
2018 |
Diabetes Mellitus
|
0.200 |
GeneticVariation
|
group |
BEFREE |
This study aimed to investigate differences in serum miR-122 levels in Chinese patients with different forms of diabetes, including T2DM, type 1 diabetes (T1DM), HNF1A variant-induced diabetes (HNF1A-DM), glucokinase variant-induced diabetes (GCK-DM), and mitochondrial A3243G mutation-induced diabetes (MDM).
|
30155490 |
2018 |
Diabetes Mellitus
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Most (6/7) patients with HNF4A variants rapidly failed TODAY treatment across study arms (hazard ratio = 5.03, P = 0.0002), while none with GCK variants failed treatment.ConclusionThe finding of 4.5% of patients with monogenic diabetes in an overweight/obese cohort of children and adolescents with T2D suggests that monogenic diabetes diagnosis should be considered in children and adolescents without diabetes-associated autoantibodies and maintained C-peptide, regardless of BMI, as it may direct appropriate clinical management.
|
29758564 |
2018 |
Diabetes Mellitus
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Among patients with neonatal diabetes (i.e. with onset within first 6 months of life) and patients with Maturity Onset Diabetes of the Young (MODY; an autosomal dominant form of diabetes), those carrying mutations in KCNJ11, ABCC8, HNF1A and HNF4A genes usually respond to oral therapy with sulphonylurea, while those bearing GCK mutations do not necessitate any treatment.
|
30086875 |
2018 |
Diabetes Mellitus
|
0.200 |
GeneticVariation
|
group |
BEFREE |
To date, no microbiome studies have been performed in maturity-onset diabetes of the young 2 (MODY2), a monogenic cause of diabetes.
|
30224347 |
2018 |
Diabetes Mellitus
|
0.200 |
GeneticVariation
|
group |
BEFREE |
CYP3A4 and GCK genetic polymorphisms are the risk factors of tacrolimus-induced new-onset diabetes after transplantation in renal transplant recipients.
|
29546446 |
2018 |
Diabetes Mellitus
|
0.200 |
AlteredExpression
|
group |
BEFREE |
However, owing to its crucial roles in glucose metabolism in the liver and in islet β-cells, the contribution of decreased GCK expression to the development of HFD-induced diabetes is unclear.
|
29915142 |
2018 |
Diabetes Mellitus
|
0.200 |
GeneticVariation
|
group |
BEFREE |
GCK-MODY carriers were found in a frequency of 3% among 1043 diabetes mellitus (DM) patients and constituted the second most numerous group of DM patients, following type 1 DM, in our centre.
|
28663157 |
2017 |
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
In this study, we propose a methodology to predict pharmacokinetic/pharmacodynamic profiles of sinogliatin (HMS-5552, RO-5305552), a novel glucokinase activator to treat diabetes mellitus, for first-in-patient (FIP) studies.
|
28000102 |
2017 |
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs.
|
28626777 |
2017 |
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
Elucidating the molecular basis of ligand-mediated control over the GCK-GKRP interaction is expected to impact the development and future refinement of therapeutic agents for diabetes and cardiovascular disease, which result from improper GKRP regulation of GCK.
|
28516783 |
2017 |
Diabetes Mellitus
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Rare missense mutations in the GCK gene were significantly over-represented in individuals with diabetes (0.5% carrier frequency) compared to controls (0.035%).
|
29207974 |
2017 |
Diabetes Mellitus
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Mutations in the transcription factors HNF1A and HNF4A and in the β-cell potassium ATP channel components cause diabetes which responds to low dose and high dose sulfonylurea agents, respectively, while glucokinase mutations require no treatment.
|
27432078 |
2016 |
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
One proband with diabetes from these families was chosen for direct sequencing of the GCK, HNF1A, HNF4A and INS genes.
|
26641800 |
2016 |